Altre lingue Xenon Pharmaceuticals Inc.

Azioni

XENE

CA98420N1050

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
40,1 ^USD	+1,52%		-0,52%	-12,94%

11/03	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM
08/03	L'insider di Xenon Pharmaceuticals ha venduto azioni per un valore di 330.290 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting	16/04
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10/04
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference	04/04
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	12/03
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days	12/03
Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	08/03
Xenon Pharmaceuticals Insider Sold Shares Worth $601,615, According to a Recent SEC Filing	08/03
Xenon Pharmaceuticals : Alberta Securities Commission British Columbia Securities Commission Ontario Securities Commission - Form 8-K	08/03
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	05/03
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024	05/03
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Xenon Pharmaceuticals Q4 Net Loss Widens	29/02
Xenon Pharmaceuticals: Q4 Earnings Snapshot	29/02
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02
Certain Warrants of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02
Certain Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 27-FEB-2024.	27/02
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update	22/02
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update	22/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Xenon Pharmaceuticals Inc.

Azioni

XENE

CA98420N1050

Altre lingue

Filtri